Investigational Use of Tissue Plasminogen Activator (t‐PA) for Occluded Central Venous Catheters
- 1 May 1990
- journal article
- research article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 14 (3) , 310-311
- https://doi.org/10.1177/0148607190014003310
Abstract
Urokinase and streptokinase are commonly used thrombolytic agents for fibrin obstructed central venous catheters. Although proven to be efficacious, these two agents have the potential to induce systemic fibrin breakdown and hemorrhage. We report our initial experience with tissue plasminogen activator (t-PA) for the treatment of occluded central venous catheters which failed urokinase. Of 25 incidents of catheter occlusion in 142 right atrial catheters, six failed to clear after an initial bolus dwell of urokinase. Five of these six catheters cleared following treatment with 2 mg/2 cc of t-PA with a mean of 1.5 bolus installations. The one catheter failure was due to catheter tip position and age of clot. No coagulation abnormalities or bleeding was observed. These data suggest that t-PA may be a safe, effective thrombolytic agent in the treatment of occluded central venous catheters. (Journal of Parenteral and Enteral Nutrition 14:310-311, 1990)This publication has 6 references indexed in Scilit:
- CONTINUOUS INFUSION OF LOW-DOSE UROKINASE IN THE TREATMENT OF CENTRAL VENOUS CATHETER THROMBOSIS IN INFANTS AND CHILDREN1989
- Thrombolytic Agents in Acute Myocardial InfarctionNew England Journal of Medicine, 1989
- Investigational use of tPA in acute strokeAnnals of Emergency Medicine, 1988
- Emergency thrombolysis in acute myocardial infarctionAnnals of Emergency Medicine, 1988
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987
- Urokinase Therapy for Silastic Catheter-Induced Intravascular Thrombi in Infants and ChildrenArchives of Surgery, 1985